{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:58Z","timestamp":1794047458898,"version":"4.8.0"},"reference-count":20,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I\/II clinical trial (GO29781) demonstrated that mosunetuzumab induced an overall response rate (ORR) of 80%, complete response (CR) rate of 60%, and a median progression-free survival (PFS) of 17.9 months in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) following at least two prior lines of systemic therapy, including alkylator and anti-CD20 antibody-based therapy. Historical data from cohorts receiving therapy for R\/R FL can provide some context for interpretation of single-arm trials. We compared the results from the mosunetuzumab trial to outcomes from a cohort of patients with R\/R FL from the LEO Consortium for Real World Evidence (LEO CReWE). We applied clinical trial eligibility criteria to the LEO CReWE cohort and utilized matching- adjusted indirect comparison weighting to balance the clinical characteristics of the LEO CReWE cohort with those from the mosunetuzumab trial. ORR (73%, 95% CI: 65-80%) and CR rates (53%, 95% CI: 45-61%) observed in the weighted LEO CReWE cohort were lower than those reported on the mosunetuzumab trial (ORR=80%, 95% CI: 70-88%; CR=60%, 95% CI: 49-70%, respectively). PFS at 12 months was similar in the weighted LEO CReWE (60%, 95% CI: 51-69%) and the mosunetuzumab (58%, 95% CI: 47-68%) trial. Sensitivity analyses examining the impact of matching variables, selection of line of therapy, and application of eligibility criteria provide context for best practices in this setting.<\/jats:p>","DOI":"10.3324\/haematol.2023.283737","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:27Z","timestamp":1701315627000},"page":"2177-2185","source":"Crossref","is-referenced-by-count":7,"title":["Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma"],"prefix":"10.3324","volume":"109","author":[{"given":"Matthew J.","family":"Maurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Richard","family":"Burack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Masaquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Shewade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"63331","doi-asserted-by":"crossref","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022; 97(12):1638-1651.","DOI":"10.1002\/ajh.26737"},{"key":"63332","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Maurer MJ, Link BK. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019; 37(2):144-152.","DOI":"10.1200\/JCO.18.00400"},{"key":"63333","doi-asserted-by":"crossref","unstructured":"Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica. 2022; 107(1):19-34.","DOI":"10.3324\/haematol.2021.278717"},{"key":"63334","doi-asserted-by":"crossref","unstructured":"Link BK, Day BM, Zhou X. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019; 184(4):660-663.","DOI":"10.1111\/bjh.15149"},{"key":"63335","doi-asserted-by":"crossref","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Vel\u00e1zquez M. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019; 184(5):753-759.","DOI":"10.1111\/bjh.15708"},{"key":"63336","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10(7):74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"63337","doi-asserted-by":"crossref","unstructured":"Salles G, Schuster SJ, Fischer L. A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL). Hemasphere. 2022; 6(7):e745.","DOI":"10.1097\/HS9.0000000000000745"},{"key":"63338","doi-asserted-by":"crossref","unstructured":"Budde LE, Sehn LH, Matasar M. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23(8):1055-1065.","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"63339","doi-asserted-by":"crossref","unstructured":"Casulo C, Larson MC, Lunde JJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022; 9(4):e289-e300.","DOI":"10.1016\/S2352-3026(22)00033-3"},{"key":"63340","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Sikirica V, Erder MH. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012; 15(6):940-947.","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"63341","doi-asserted-by":"crossref","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018; 38(2):200-211.","DOI":"10.1177\/0272989X17725740"},{"key":"63342","doi-asserted-by":"crossref","unstructured":"Albarmawi H, Nagarajan M, Onukwugha E. Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients. Future Oncol. 2020; 16(8):353-365.","DOI":"10.2217\/fon-2019-0660"},{"key":"63343","doi-asserted-by":"crossref","unstructured":"Xie C, Li R, Huang X, Chihara D, Flowers CR. The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis. Clin Lymphoma Myeloma Leuk. 2022; 22(10):e938-e946.","DOI":"10.1016\/j.clml.2022.06.014"},{"key":"63344","doi-asserted-by":"crossref","unstructured":"Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020; 20(10):661-667.","DOI":"10.1016\/j.clml.2020.05.008"},{"key":"63345","doi-asserted-by":"crossref","unstructured":"Rutherford SC, Yin J, Pederson L. Relevance of bone marrow biopsies for response assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023; 41(2):336-342.","DOI":"10.1200\/JCO.21.02301"},{"key":"63346","doi-asserted-by":"crossref","unstructured":"Thompson CA, Ghesquieres H, Maurer MJ. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014; 32(31):3506-3512.","DOI":"10.1200\/JCO.2014.55.7561"},{"key":"63347","doi-asserted-by":"crossref","unstructured":"Goldman ML, Mao JJ, Strouse CS. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer. 2021; 127(18):3390-3402.","DOI":"10.1002\/cncr.33660"},{"key":"63348","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021; 5(20):4149-4155.","DOI":"10.1182\/bloodadvances.2020003848"},{"key":"63349","doi-asserted-by":"crossref","unstructured":"Salles G, Schuster SJ, Dreyling M. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022; 6(22):5835-5843.","DOI":"10.1182\/bloodadvances.2022008150"},{"key":"63350","doi-asserted-by":"crossref","unstructured":"Ghione P, Palomba ML, Patel A. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/ refractory follicular lymphoma. Blood. 2022; 140(8):851-860.","DOI":"10.1182\/blood.2021014375"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283737\/76377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283737\/77185","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11360\/76377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:19Z","timestamp":1794045919000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283737","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}